RPHM Stock Price, Reneo Pharmaceuticals, . Quote, Chart

Market Summary

USD1.74+0.08

Delayed

4.82%

RPHM Stock Price

View Fullscreen

RPHM RSI Chart

RPHM Valuation

Market Cap

58.2M

Price/Earnings (Trailing)

-0.82

Price/Free Cashflow

-0.77

RPHM Price/Earnings (Trailing)

RPHM Profitability

Return on Equity

-87.03%

Return on Assets

-83.54%

Free Cashflow Yield

-130.55%

RPHM Fundamentals

RPHM Earnings

Earnings (TTM)

-70.7M

Earnings Growth (Yr)

44.22%

Earnings Growth (Qtr)

64.23%

Breaking Down RPHM Revenue

Last 7 days

-3.9%

Last 30 days

-1.7%

Last 90 days

5.5%

Trailing 12 Months

-77.4%

How does RPHM drawdown profile look like?

RPHM Financial Health

Current Ratio

29.82

RPHM Investor Care

Buy Backs (1Y)

0.70%

Diluted EPS (TTM)

-2.17

Tracking the Latest Insider Buys and Sells of Reneo Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 28, 2023	hall ashley	acquired	28,125	1.8	15,625	chief development officer
Aug 28, 2023	hall ashley	sold	-98,057	6.2757	-15,625	chief development officer
Jul 26, 2023	grey michael g	gifted	-	-	-50,000	executive chairman
Jun 23, 2023	novo holdings a/s	sold	-709,740	7.0974	-100,000	-
May 08, 2023	o'donnell niall	bought	1,000,000	8.00	125,000	-
Sep 01, 2022	cruse michael	bought	25,447	3.393	7,500	chief operating officer
Aug 31, 2022	grey michael g	acquired	98,500	1.97	50,000	executive chairman
Aug 31, 2022	cruse michael	bought	10,307	3.209	3,212	chief operating officer
Aug 30, 2022	cruse michael	bought	5,892	3.1938	1,845	chief operating officer
Aug 30, 2022	cruse michael	bought	3,081	3.16	975	chief operating officer

Which funds bought or sold RPHM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-126,299	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-31.74	-998	2,420	-%
May 15, 2024	CSS LLC/IL	unchanged	-	1,217	33,678	-%
May 15, 2024	LMR Partners LLP	sold off	-100	-72,000	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-146,208	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-28.43	-75,180	216,778	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-10.00	-352,980	4,975,020	0.52%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-254,224	-	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	28,590	28,590	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	new	-	26,892	26,892	-%

Are Funds Buying or Selling RPHM?

Are funds buying RPHM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RPHM

No. of Funds

Unveiling Reneo Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 08, 2024	new enterprise associates 15, l.p.	14.3%	4,785,494	SC 13D/A
Feb 05, 2024	octagon capital advisors lp	6.75%	2,250,000	SC 13G
Jan 17, 2024	bml investment partners, l.p.	4.1%	1,364,229	SC 13G
Dec 26, 2023	tang capital partners lp	996%	3,330,000	SC 13D
Dec 15, 2023	novo holdings a/s	0%	0	SC 13D/A
May 30, 2023	rivervest venture fund iii, l.p.	0.97%	328,094	SC 13D/A
May 15, 2023	novo holdings a/s	10.2%	3,430,377	SC 13D/A
May 09, 2023	carlyle group inc.	8.2%	2,730,457	SC 13D/A

Recent SEC filings of Reneo Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	3	Insider Trading
May 13, 2024	8-K	Current Report
May 13, 2024	425	Prospectus Filed
May 08, 2024	SC 13D/A	13D - Major Acquisition
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
Apr 26, 2024	10-K/A	Annual Report
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report

Peers (Alternatives to Reneo Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Reneo Pharmaceuticals, Inc. News

Latest updates

Reneo Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-21.2%	85.00	107	130	148	99.00	108	123	134	144	154	163	171	95.00	55.00
Current Assets	-21.3%	84.00	107	129	146	97.00	106	121	132	143	154	163	171	94.00	55.00
Cash Equivalents	-26.3%	20.00	28.00	12.00	9.00	30.00	20.00	62.00	118	121	125	126	140	91.00	54.00
Net PPE	-23.9%	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-82.0%	3.00	19.00	15.00	16.00	12.00	8.00	10.00	9.00	9.00	7.00	7.00	4.00	4.00	5.00
Current Liabilities	-84.5%	3.00	18.00	14.00	14.00	10.00	7.00	9.00	8.00	8.00	6.00	6.00	3.00	4.00	5.00
Shareholder's Equity	-8.3%	81.00	89.00	115	133	87.00	100	112	124	135	147	156	168	-	-
Retained Earnings	-3.9%	-226	-218	-190	-171	-151	-136	-123	-110	-97.76	-84.73	-74.10	-61.40	-97.80	-44.96
Additional Paid-In Capital	0.4%	308	307	305	304	239	237	235	234	233	232	230	229	3.00	3.00
Shares Outstanding	0%	33.00	33.00	34.00	34.00	25.00	25.00	24.00	24.00	24.00	24.00	24.00	21.00	2.00	2.00
Float	-	-	-	-	151	-	-	-	39.00	-	-	-	93.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-6.2%	-21,014	-19,782	-18,700	-16,200	-9,000	-15,613	-10,794	-11,956	-8,999	-10,021	-9,672	-9,701	-8,589	-5,411	-5,741	-2,937	-4,447
Share Based Compensation	-18.3%	1,078	1,319	1,429	1,207	1,157	1,217	990	1,006	1,107	1,421	1,145	854	471	129	84.00	88.00	92.00
Cashflow From Investing	-65.4%	13,757	39,776	21,250	-69,011	18,507	-26,917	-45,435	9,083	5,427	8,153	-4,509	-26,995	-25.00	-16.00	1,193	1,000	5,199
Cashflow From Financing	100.0%	-	-4,128	173	63,811	1,009	325	97.00	43.00	6.00	119	222	85,843	46,222	47,195	51.00	-	26.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RPHM Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,942	$ 10,991
General and administrative	4,622	5,132
Total operating expenses	9,564	16,123
Loss from operations	(9,564)	(16,123)
Other income:
Other income	1,138	1,016
Net loss	(8,426)	(15,107)
Unrealized (loss) gain on short-term investments	(20)	55
Comprehensive loss	$ (8,446)	$ (15,052)
Net loss per share attributable to common stockholders, basic	$ (0.25)	$ (0.6)
Net loss per share attributable to common stockholders, diluted	$ (0.25)	$ (0.6)
Weighted-average shares used in computing net loss per share, basic	33,420,808	25,036,410
Weighted-average shares used in computing net loss per share, diluted	33,420,808	25,036,410

RPHM Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 20,375	$ 27,632
Short-term investments	62,460	75,331
Prepaid expenses and other current assets	1,092	3,659
Total current assets	83,927	106,622
Property and equipment, net	102	134
Right-of-use assets	546	599
Other non-current assets	64	81
Total assets	84,639	107,436
Current liabilities:
Accounts payable	676	8,717
Accrued expenses	1,807	9,129
Operating lease liabilities, current portion	331	331
Total current liabilities	2,814	18,177
Operating lease liabilities, less current portion	576	642
Performance award	7	7
Total liabilities	3,397	18,826
Commitments and contingencies
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 33,420,808 shares issued and outstanding at March 31, 2024 and December 31, 2023	3	3
Additional paid-in capital	308,151	307,073
Accumulated deficit	(226,900)	(218,474)
Accumulated other comprehensive (loss) income	(12)	8
Total stockholders' equity	81,242	88,610
Total liabilities and stockholders' equity	$ 84,639	$ 107,436

About Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

CEO	Mr. Gregory J. Flesher
WEBSITE	https://reneopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	51

Reneo Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Reneo Pharmaceuticals, Inc.? What does RPHM stand for in stocks?

RPHM is the stock ticker symbol of Reneo Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Reneo Pharmaceuticals, Inc. (RPHM)?

As of Fri May 17 2024, market cap of Reneo Pharmaceuticals, Inc. is 58.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPHM stock?

You can check RPHM's fair value in chart for subscribers.

What is the fair value of RPHM stock?

You can check RPHM's fair value in chart for subscribers. The fair value of Reneo Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Reneo Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPHM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Reneo Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether RPHM is over valued or under valued. Whether Reneo Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Reneo Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPHM.